| Bioactivity | EGFR-IN-57 (Compound 25a) is a potent, orally active EGFR-TK inhibitor with an IC50 of 0.054 µM. EGFR-IN-57 also inhibits VEGFR-2, CK2α, topoisomerase IIβ and tubulin polymerization with IC50 values of 0.087, 0.171, 0.13 and 3.61 µM, respectively. EGFR-IN-57 induces cell cycle arrest at G2/M and pre-G1 phases. EGFR-IN-57 induces cancer cell apoptosis[1]. |
| Name | EGFR-IN-57 |
| CAS | 2492382-37-1 |
| Formula | C22H15N3O2S |
| Molar Mass | 385.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Warda ET, et al. New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation. Bioorg Med Chem. 2020 Nov 1;28(21):115674. |
EGFR-IN-57
CAS: 2492382-37-1 F: C22H15N3O2S W: 385.44
EGFR-IN-57 (Compound 25a) is a potent, orally active EGFR-TK inhibitor with an IC50 of 0.054 µM. EGFR-IN-57 also inhibi
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.